9 completed. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 9 |
Follow Oppositional Defiant Disorder: new trials by email Literature Review of Oppositional Defiant Disorder trials Research Report on Oppositional Defiant Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 Mexidol, Placebo, Mexidol + Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms | Phase 3 | Completed | Pharmasoft | 333 | 2019-07-13 | 2025-08-17 |
| Treatment of Children With Peer Related Aggressive Behavior Treatment Program for Children with Aggressive Behavior, Play group - Oppositional Defiant Disorder | Phase 3 | Completed | University of Cologne | 100 | 2011-01-01 | 2014-04-15 |
| Strongest Families Ontario (Formerly the Family Help Program) Strongest Families Intervention (formerly Family Help) - Oppositional Defiant Disorder, Behaviour Disorder | Phase 3 | Completed | IWK Health Centre | 172 | 2010-02-01 | 2016-09-02 |
| Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Incredible Years Program - Attention Deficit Disorder With Hyperactivity, Attention Deficit and Disruptive Behavior Disorders | Phase 3 | Completed | Tufts Medical Center | 345 | 2006-11-01 | 2013-02-12 |
| An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). atomoxetine 0.5 mg/kg/day, placebo, atomoxetine 1.2 mg/kg/day - Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder | Phase 3 | Completed | Eli Lilly and Company | 139 | 2004-10-01 | 2010-01-18 |
| Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD atomoxetine hydrochloride, placebo - Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder | Phase 3 | Completed | Eli Lilly and Company | 226 | 2003-12-01 | 2008-10-31 |
| Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Risperdal - Oppositional Defiant Disorder, Conduct Disorder | Phase 3 | Completed | Ohio State University | 30 | 1999-05-01 | 2016-06-23 |
| A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Risperidone oral solution - Conduct Disorder, Oppositional Defiant Disorder | Phase 3 | Completed | Janssen Pharmaceutica N.V., Belgium | 110 | 1997-09-01 | 2011-01-24 |
| A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation risperidone - Conduct Disorder, Disruptive Behavior Disorder | Phase 3 | Completed | Janssen Pharmaceutica N.V., Belgium | 118 | 2011-01-24 |
Attention Deficit Disorder with Hyperactivity (7) · Attention Deficit and Disruptive Behavior Disorders (3) · Conduct Disorder (3) · Adjustment Disorders (1) · Anxiety Disorders (1) · Bipolar Disorder (1) · Child Development Disorders, Pervasive (1) · Disruptive, Impulse Control, and Conduct Disorders (1) · Impulsive Behavior (1) · Mental Disorders (1) · Neurodevelopmental Disorders (1) · Spasm (1)
Mental Disorders (8) · Neurodevelopmental Disorders (8) · Attention Deficit and Disruptive Behavior Disorders (6) · Behavior (1) · Bipolar and Related Disorders (1) · Mood Disorders (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Trauma and Stressor Related Disorders (1)
Risperidone (3) · Atomoxetine Hydrochloride (2) · emoxypine succinate (1)
Eli Lilly and Company (2) · Janssen Pharmaceutica N.V., Belgium (2) · IWK Health Centre (1) · Ohio State University (1) · Pharmasoft (1) · Tufts Medical Center (1) · University of Cologne (1)
Germany (2) · United States (2) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · Finland (1) · Italy (1) · Netherlands (1) · Russia (1) · Spain (1) · United Kingdom (1)
Anja Goertz-Dorten, PhD (1) · Anna N. Platonova, Cand.Med.Sci, MD (1) · Anna S. Nezabudkina, MD (1) · Christopher Sheldrick, PhD (1) · Dina D. Gainetdinova, Dr.Med.Sci, Prof. (1) · Elena M. Kryukova, MD (1) · Elena V. Levitina, Dr.Med.Sci, Prof. (1) · Ellen C. Perrin, MD (1) · Elmira S. Sagutdinova, Cand.Med.Sci, MD (1) · Irina N. Vakula, MD (1) · Jannette McMenamy, PhD (1) · Michael G Aman, Ph.D. (1)
PMID 25019647, PMID 12153826, PMID 12218423, PMID 24190691, PMID 29347904
R01MH076244 (1)